Results 51 to 60 of about 2,405,617 (334)

An uncommon organism in ascitic fluid

open access: yesAnnals of Saudi Medicine, 2014
Ann Saudi Med 2014 July-August www.annsaudimed.net 358 A 32-year-old nonalcoholic, nondiabetic male, who had a history of mild acute biliary pancreatitis one year back and who subsequently underwent laparoscopic cholecystectomy, presented with abdominal pain and abdominal distension for almost four months.
Vishal Khurana   +3 more
openaire   +3 more sources

Prostate-Specific Antigen in Ascitic Fluid [PDF]

open access: yesClinical Chemistry, 1997
Although previously thought to be produced almost exclusively by the epithelial cells of the prostate (1), prostate-specific antigen (PSA) is produced and secreted by several extraprostatic sources (2)(3). Considering the high degree of homology of PSA with the human glandular kallikrein (hKGK1) (4)(5) and the activation of the kallikrein–kinin system ...
MANNELLO, FERDINANDO   +3 more
openaire   +3 more sources

Performance of Xpert MTB/RIF on Ascitic Fluid Samples for Detection of Abdominal Tuberculosis

open access: yesJournal of Laboratory Physicians, 2017
Background: Diagnosis of abdominal tuberculosis (TB) from ascitic fluid samples using routinely available diagnostic methods is challenging due to its paucibacillary nature.
S. Rufai   +5 more
semanticscholar   +1 more source

Ascitic fluid analysis for the differentiation of malignancy related and nonmalignant ascites [PDF]

open access: yes, 1991
The authors tried to differentiate malignancy-related from nonmalignant ascites with a sequence of sensitive followed by specific ascitic-fluid parameters. There were four results of this study. First, of nine parameters investigated in a first series of
Paumgartner, Gustav   +4 more
core  

Correlation of Tumour Markers in Ascitic Fluid and Serum: Are Measurements of Ascitic Tumour Markers a Futile Attempt?

open access: yes, 2009
Correlations between tumour markers in ascitic fluid and serum were investigated to determine whether ascitic fluid analysis had any diagnostic advantage over serum in 91 adults with ascites (55 malign; 36 benign).
Celik, Y.   +5 more
core   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch   +13 more
wiley   +1 more source

From the Pharynx to the Abdomen: A Case of Primary Peritonitis

open access: yesActa Médica Portuguesa, 2018
Primary peritonitis usually occurs in patients with comorbidities previously diagnosed with ascites. However, a primary peritoneal infection in previously healthy patients may also ensue.
Miguel Lourenço Varela   +3 more
doaj   +1 more source

Usefulness of ascitic fluid lactoferrin levels in patients with liver cirrhosis

open access: yesBMC Gastroenterology, 2016
BackgroundAlthough elevated levels of lactoferrin provide a biomarker for inflammatory bowel diseases and colorectal cancer, the clinical significance of these elevated levels in ascitic fluid of patients with ascites caused by liver cirrhosis is limited.
Sang Soo Lee   +11 more
semanticscholar   +1 more source

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

open access: yesFEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart   +7 more
wiley   +1 more source

Matrix metalloproteinase‐9 regulates cell adhesion and membrane protrusive activity of ovarian cancer cells

open access: yesFEBS Open Bio, EarlyView.
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy